All News

cost.healthcare.jpg

Cost-Effectiveness of Biosimilars vs Leflunomide

Jack Cush, MD

An economic evaluation of 25 099 rheumatoid arthritis patients found that treatment with biosimilar disease-modifying antirheumatic drugs (DMARDs) were cost-effective compared with the conventional DMARD, leflunomide.

Read Article
guidelines.recommendations.jpg

ICYMI: 2023 EULAR Psoriatic Arthritis Recommendations

Jack Cush, MD

EULAR has updated its treatment recommendations from the prior 2019 guidelines, since there have been several newly developed agents. The updated guidance includes 7 overarching principles and 11 recommendations regarding treatment strategy and pharmacological therapies.

Read Article
Malar,rash,SLE, Lupus

ICYMI: JAMA: SLE Review

Jack Cush, MD

Drs. Caroline Siegel and Lisa Sammaritano (from HSS in NYC) have published an impressive overview of systemic lupus erythematosus (SLE) in JAMA. This timely, well-written review covers the many complexities of this multi-organ disorder that affects nearly 3.4 million people worldwide.

Read Article
RheumNow Podcast square

Future Big BiTEs (6.28.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and regulatory announcements from the past week on RheumNow.com.

Read Article
LBP,back,man,spine

Low Back Pain? Take a Walk!

Jack Cush, MD

A randomised controlled trial of adults with recurrent low back pain (LBP) has shown that a program of progressive walking and education intervention significantly reduced low back pain recurrence.

Read Article
FDA adverse event study of JAKi in #RA assoc w/ signif more VTE, ischemic heart Dz, & tachyarrhythmias. 75,407 on JAKi vs 303,278 on biologics (TNFi, RTX, TCZ); JAK had more VTE (ROR=2.11), CVA (ROR=1.25), IHD (1.23), arrhythmias (1.15 ), esp in 1st yr. https://t.co/BmNPk6zN6o https://t.co/fbzHQmPmH5

Links:

Dr. John Cush RheumNow ( View Tweet)
RT @drdavidliew I have to say: upadacitinib looks very decent for GCA. Not a panacea, but it definitely does something & good safety during trial. Would love to eventually see: - H2H comparative effect vs toci, secukinumab - structural outcomes - long-term safety #EULAR2024

Dr. John Cush RheumNow ( View Tweet)

Future Big BiTEs (6.28.2024) Dr. Jack Cush reviews the news, journal articles and regulatory announcements from the past week on https://t.co/V10S4oVFsv. https://t.co/AKb2qmQ2nf https://t.co/3nKuEXteXS

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US. The US FDA has also approved 2 other biosimilars to ustekinumab, including ustekinumab-aekn (Selarsdi) and ustekinumab-auub (Wezlana). https://t.co/BgYQm39aEB https://t.co/XZhnHxPaP0

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA has approved risankizumab (Skyrizi) to treat adults with moderately to severely active ulcerative colitis (UC), making it the IL-23 inhibitor approved for UC. Approval is based on two large phase 3 clinical trials (COMMAND, INSPIRE) https://t.co/wNSZdWWDO1 https://t.co/mlwxIrdUD2

Links:

Dr. John Cush RheumNow ( View Tweet)
JAK inhibitors have been used as adjunctive therapy to reduce flammation arising with checkpoint inhibitor use in cancer (Hodgkins, Lung CA), using itacitinib w/ pembrolizumab or ruxolitinib & nivolumab improved trial outcomes https://t.co/eF6wO72D80 https://t.co/IFDYuI71X5

Links:

Dr. John Cush RheumNow ( View Tweet)
Moonlake has announced its phase 3 program to develop Sonelokimab (M1095) a dual inhibitor of IL-17A & IL-17F for use in Psoriatic arthritis. IZAR-1 & IZAR-2 Ph 3 DBPCT will enroll 1,500 adults w/ active PsA, w/ ACR 50 endpoint at Week 16 https://t.co/y3UvOF4M5i https://t.co/iSUrkhIXbh

Links:

Dr. John Cush RheumNow ( View Tweet)
JAK Inhibitors in GCA Trials are underway evaluating the potential benefits of JAKi in GCA patients who are refractory to standards of care. An observational real-world analysis of a small worldwide cohort suggests the utility of JAKi in GCA. https://t.co/d4IsqBgkxQ https://t.co/PIDhwzgNym

Links:

Dr. John Cush RheumNow ( View Tweet)
Difficult-to-Treat Psoriasis This meta-analysis of psoriasis treatments shows that biologic therapies may be less effective in certain psoriasis (PSO) patients, particularly those who are older, smokers, with higher BMI an prior exposure to biologics. https://t.co/OWzmYShqBs https://t.co/u1995MAB15

Links:

Dr. John Cush RheumNow ( View Tweet)
RT @yuz6yusof #EULAR2024 Cutaneous #lupus is variable & can be difficult to treat. Promising post-hoc data frm Phase 2 RCT showing Deucravacitinib (Tyk2-i) led to improvement & sustained CLASI-50 response in all subtypes (ACLE, SCLE, Chonic and Discoid) #EULARBEST

Dr. John Cush RheumNow ( View Tweet)

Vilobelimab, an anticomplement factor 5a (C5a) antibody, shown in this case report to be effective in (difficult to treat) pyoderma gangrenosum. https://t.co/P241Knoco6 https://t.co/hrCxOv8SEA

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA has approved risankizumab (Skyrizi) to treat adults with moderately to severely active ulcerative colitis (UC), making it the IL-23 inhibitor approved for UC. Approval is based on two large phase 3 clinical trials (COMMAND, INSPIRE) https://t.co/JWX5SBEvT5 https://t.co/MrMFmOyQqa

Links:

Dr. John Cush RheumNow ( View Tweet)
In patients with bio-naïve r-axSpA, Ixekizumab treatment for 16 weeks decreased erosion scores and increased backfill scores, particularly in the IXE Q2W group, consistent with rapid tissue repair #EULAR2024 Abst OP0046 @RheumNow https://t.co/bVYjnBqpaf

Links:

Dr. John Cush RheumNow ( View Tweet)

lanalumab (anti-baff) LTE 1/3 to 1/2 LLDAS/DORIS remission at 52 wks, reduction autoabs etc - looking very promising @rheumnow #EULAR2024

Dr. John Cush RheumNow ( View Tweet)

Moonlake has announced its phase 3 program to develop Sonelokimab (M1095) a dual inhibitor of IL-17A & IL-17F for use in Psoriatic arthritis. IZAR-1 & IZAR-2 Ph 3 DBPCT will enroll 1,500 adults w/ active PsA, w/ ACR 50 endpoint at Week 16 https://t.co/NUZ3cc4bUx https://t.co/nGP10y3Kuw

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×